Sign In
Buy CNS
$70.20
-1.00 (-1.40%)
At Close: Jun 03, 2026
Corero Network Security Leads in 2025 SPARK Matrix With Higher Customer Impact
07:00am, Thursday, 24'th Jul 2025
Elevated ranking reflects market demand for SmartWall ONE™ and the new CORE solution LONDON , July 24, 2025 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the DDoS protection spe
Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Compan
CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference
08:45am, Tuesday, 22'nd Jul 2025
– Video webcast now available on-demand HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing i
Cohen & Steers Reports Solid Q2
11:49am, Monday, 21'st Jul 2025
Cohen & Steers (CNS 1.95%), a global investment manager known for its focus on real assets and alternative income, released its second quarter fiscal 2025 earnings on July 17, 2025. Management comment
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
07:30am, Monday, 21'st Jul 2025
Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses
Cohen & Steers, Inc. (CNS) Q2 2025 Earnings Call Transcript
12:25pm, Friday, 18'th Jul 2025
Cohen & Steers, Inc. (NYSE:CNS ) Q2 2025 Earnings Conference Call July 18, 2025 10:00 AM ET Company Participants Brian William Heller - Senior VP & Corporate Counsel Jon Young Cheigh - President & Chi
CNS Pharmaceuticals Announces Reverse Stock Split
08:00am, Friday, 18'th Jul 2025
HOUSTON, TX / ACCESS Newswire / July 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr
COHEN & STEERS REPORTS RESULTS FOR SECOND QUARTER 2025
04:13pm, Thursday, 17'th Jul 2025
NEW YORK , July 17, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended June 30, 2025. The earnings release along with the accompanying earnings pres
AB or CNS: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 11'th Jul 2025
Investors looking for stocks in the Financial - Investment Management sector might want to consider either AllianceBernstein (AB) or Cohen & Steers Inc (CNS). But which of these two stocks presents in
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
07:30am, Thursday, 10'th Jul 2025
The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for June 2025
04:30pm, Wednesday, 09'th Jul 2025
NEW YORK , July 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.9 billion as of June 30, 2025, an increase of $321 million from asse
Cohen & Steers, Inc. to Release Second Quarter 2025 Results on July 17, 2025
04:25pm, Wednesday, 09'th Jul 2025
NEW YORK , July 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release second quarter 2025 results after the market closes on Thursday, July 17, 2025. The earnin
CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment
09:32am, Wednesday, 09'th Jul 2025
HOUSTON, TX / ACCESS Newswire / July 9, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Cooper University Health Care Selects Corero Network Security to Implement Zero Trust Admission Control
07:00am, Monday, 07'th Jul 2025
Healthcare-first deployment of Corero's CORE ZTAC delivers real-time, zero trust protection across Cooper's digital infrastructure LONDON , July 7, 2025 /PRNewswire/ -- Corero Network Security (AIM: C
